Dendreon Corp (DNDN)

0.06
0.00 6.02
NASDAQ : Health Care
Prev Close 0.06
Open 0.06
Day Low/High 0.06 / 0.06
52 Wk Low/High 0.04 / 3.46
Volume 1.37M
Avg Volume 5.11M
Exchange NASDAQ
Shares Outstanding 158.72M
Market Cap 20.16M
EPS -1.95
P/E Ratio N/A
Div & Yield N.A. (N.A)
Dendreon Announces Second Quarter 2012 Results

Dendreon Announces Second Quarter 2012 Results

July 30, 2012--Dendreon Corporation (NASDAQ:DNDN) today reported results for the quarter ended June 30, 2012.

The Next Big Thing in Biotech: Dendreon/Vertex Earnings

The Next Big Thing in Biotech: Dendreon/Vertex Earnings

Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.

Dendreon Corp (DNDN): Today's Featured Drugs Winner

Dendreon Corp (DNDN): Today's Featured Drugs Winner

Dendreon was a winner within the drugs industry, rising 32 cents (5.2%) to $6.53 on heavy volume.

4 Biotech Stocks Under $10 With Relative Strength

4 Biotech Stocks Under $10 With Relative Strength

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Dendreon To Host Conference Call On July 30 To Announce Second Quarter Financial Results And Webcast Presentation At Upcoming Conference

Dendreon To Host Conference Call On July 30 To Announce Second Quarter Financial Results And Webcast Presentation At Upcoming Conference

July 12, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Monday, July 30, 2012, at 4:30 p.

John H. Johnson Assumes Role Of Chairman

John H. Johnson Assumes Role Of Chairman

July 3, 2012–-Dendreon Corporation (NASDAQ: DNDN) today announced that John H.

Obamacare-Proofing Your Portfolio

Obamacare-Proofing Your Portfolio

The Affordable Care Act accelerates trends to lower per-patient costs and vertical integration.

Dendreon Corp (DNDN): Today's Featured Health Care Loser

Dendreon Corp (DNDN): Today's Featured Health Care Loser

Dendreon was a leading decliner within the health care sector, falling 32 cents (-4.3%) to $7.20 on average volume.

Medivation, Not Dendreon, Likely Prostate Cancer Takeout Target, Analyst Says

Medivation, Not Dendreon, Likely Prostate Cancer Takeout Target, Analyst Says

Medivation could be acquired for a 55% premium to its current stock price, Jefferies says.

Cramer's 'Mad Money' Recap: Putting Europe Into Perspective

Cramer's 'Mad Money' Recap: Putting Europe Into Perspective

There are opportunities in America that are being created by Europe's problems, Cramer said.

5 Stocks Under $10 Soaring Higher

5 Stocks Under $10 Soaring Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Stocks Under $10: #SU10chat Recap

Stocks Under $10: #SU10chat Recap

Portfolio Manager David Peltier recaps the highlights of his monthly live Twitter chat.

Cramer's 'Mad Money' Recap: Savor Today's Rally

Cramer's 'Mad Money' Recap: Savor Today's Rally

It's a rare day when Europe's central bank exudes confidence and U.S. companies take center stage with investors, Cramer said.

Dendreon Stock Hits New 52-Week Low (DNDN)

Dendreon Stock Hits New 52-Week Low (DNDN)

Dendreon (Nasdaq:DNDN) hit a new 52-week low Monday as it is currently trading at $6.41, below its previous 52-week low of $6.46 with 3.5 million shares traded as of 10 a.m. ET. Average volume has been 6.7 million shares over the past 30 days.

ASCO 2012 Live Blog -- Monday

ASCO 2012 Live Blog -- Monday

TheStreet's biotech columnist Adam Feuerstein brings you live coverage of the ASCO cancer conference.

ASCO '12 Stocks: Winners and Losers

ASCO '12 Stocks: Winners and Losers

Snap judgments in biotech and drug stocks after a weekend spent at the ASCO cancer meeting.

ASCO 2012 Live Blog -- Saturday

ASCO 2012 Live Blog -- Saturday

TheStreet's biotech columnist Adam Feuerstein brings you live coverage of ASCO, the Super Bowl of cancer drug medical conferences.

J&J Scores Big With Prostate Cancer Pill

J&J Scores Big With Prostate Cancer Pill

J&J's Zytiga improves survival and delays tumor worsening in 'pre-chemo' prostate cancer patients.

Dendreon Announces Webcast Presentations At Upcoming Conferences

Dendreon Announces Webcast Presentations At Upcoming Conferences

May 25, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the following conferences: Jefferies 2012 Global Healthcare Conference in New York City on June 4,...

Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer

Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

The Next Big Thing in Biotech: ASCO Conference

The Next Big Thing in Biotech: ASCO Conference

Senior columnist Adam Feuerstein says the ASCO Cancer Conference is the next big thing in biotech.

Dendreon Announces Data Presentation At The 2012 American Urological Association Annual Meeting

Dendreon Announces Data Presentation At The 2012 American Urological Association Annual Meeting

May 21, 2012–Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May...

Dendreon Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Dendreon Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Dendreon Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)

Dendreon Announces Presentation Of PROVENGE Data At The 2012 American Society Of Clinical Oncology Annual Meeting

Dendreon Announces Presentation Of PROVENGE Data At The 2012 American Society Of Clinical Oncology Annual Meeting

May 16, 2012--Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting American Society...

Dendreon Management Presents At Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript)

Dendreon Management Presents At Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript)

Dendreon Management Presents at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript)

Dendreon Stock Gaps Down On Today's Open (DNDN)

Dendreon Stock Gaps Down On Today's Open (DNDN)

Shares of Dendreon (Nasdaq:DNDN) were gapping down Tuesday morning with an open price 13.6% lower than Monday's closing price. The stock closed at $11.69 yesterday and opened today's trading at $10.10.

Dendreon's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dendreon's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dendreon's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Dendreon Reports Net PROVENGE Product Revenues Of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth

Dendreon Reports Net PROVENGE Product Revenues Of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth

May 7, 2012--Dendreon Corporation (Nasdaq:DNDN) today reported results for the quarter ended March 31, 2012.

Top 10 Earnings Coming Monday

Top 10 Earnings Coming Monday

Out of the 100 companies reporting, these are the most active and potentially market-moving.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.